EP0816356A1 — 1-(2-(1-piperidinyl)-1-ethyl)-1,3-dihydro-2H-benzimidazole derivatives and their pharmaceutical use
Assigned to Eli Lilly and Co Ltd · Expires 1998-01-07 · 28y expired
What this patent protects
A pharmaceutical compound of the formula in which X is -CR'R"- or -C(O)- where R' and R" are each hydrogen, C 1-6 alkyl or optionally substituted phenyl, Y is oxygen or sulphur, R 1 , R 2 and R 7 are each selected from halo, C 1-4 alkyl, C 1-4 alkoxy, trifluorometh…
USPTO Abstract
A pharmaceutical compound of the formula in which X is -CR'R"- or -C(O)- where R' and R" are each hydrogen, C 1-6 alkyl or optionally substituted phenyl, Y is oxygen or sulphur, R 1 , R 2 and R 7 are each selected from halo, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethyl, nitro, cyano, amino, phenyl, phenoxy, benzyl, benzyloxy, acylamino, C 1-4 alkylsulphonylamino, C 1-4 alkylthio, C 1-4 alkylsulphonyl, carboxamido, sulphonamido, hydroxy, methylenedioxy, carboxy, and heteroaryl, R 3 , R 4 , R 5 and R 6 are each hydrogen, C 1-6 alkyl or optionally substituted phenyl, n, m and p are each 0, 1, 2 or 3; or a salt or ester thereof.
Drugs covered by this patent
- Addyi (FLIBANSERIN) · Sprout Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.